Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$2.18 USD
-0.01 (-0.46%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $2.18 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SAVA 2.18 -0.01(-0.46%)
Will SAVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAVA
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
Is the Future Bleak for SAVA Stock Following Another Setback?
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SAVA
Cassava Sciences (SAVA) Appoints New Chief Medical Officer
Cassava Sciences taps Joseph Hulihan as chief medical officer
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer | SAVA Stock News
Cassava Sciences appoints Hulihan as Chief Medical Officer
Cassava Sciences (SAVA) Reveals Positive Study Results for Epilepsy Treatment